Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/10495/39793
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.authorLópez Osorio, María Camila-
dc.contributor.authorHoyos Duque, Sergio Iván-
dc.contributor.authorRestrepo Gutiérrez, Juan Carlos-
dc.contributor.authorNavas Navas, María Cristina-
dc.contributor.authorUsme Ciro, José Aldemar-
dc.contributor.authorMartínez, José William-
dc.contributor.authorPeláez Carvajal, Dioselina-
dc.contributor.authorHernández, Javier-
dc.date.accessioned2024-06-08T19:50:19Z-
dc.date.available2024-06-08T19:50:19Z-
dc.date.issued2022-
dc.identifier.citationLópez-Osorio MC, Usme-Ciro JA, Martínez JW, Peláez-Carvajal D, Hernández J, Hoyos S, Restrepo JC, Navas MC. Genetic diversity of hepatitis C virus and resistance associated substitutions to direct-acting antiviral treatment in Colombia. Virus Res. 2022 Sep;318:198847. doi: 10.1016/j.virusres.2022.198847.spa
dc.identifier.issn0168-1702-
dc.identifier.urihttps://hdl.handle.net/10495/39793-
dc.description.abstractABSTRACT: Hepatitis C virus (HCV) infection is one of the leading risk factors for end-stage liver disease development worldwide. This RNA virus displays high genetic diversity with 8 genotypes and 96 subgenotypes with heterogeneous geographical distribution around the world. In this study, we carried out an active case finding of individuals with a history of transfusion events before 1996 in three cities in Colombia. Then, the characterization of the HCV genotypes, subgenotypes, and resistance associate substitutions (RAS) was performed in samples positives for antibodies anti-HCV + from this study population. In addition, samples from PWID and patients with end-stage liver disease submitted to liver transplantation were included in the phylogenetic and RAS analysis. The 5'UTR, NS5A, and NS5B regions of the HCV genome were amplified in serum or liver explants samples. After the edition, assembly, and alignment of the sequences, genotyping through phylogenetic analysis was performed using IQTREE V2.0.5 based on the maximum likelihood approach. The identification of RAS was carried out by alignments based on the reference sequence (GenBank NC_004102). Two hundred sixty individuals with blood transfusion events before 1996 were recruited. The seroprevalence of antibodies anti-HCV was 2.69% in this population. The HCV genotypes 1, 2, and 4 and subgenotypes 1a, 1b, 2a, 4a and 4d were characterized in samples of the study populations. Three RAS (Q30R, C316N, and Y93H) were identified in samples obtained from 2 individuals who received blood transfusion before 1996 and without previous antiviral treatment and 6 samples obtained from patients with end-stage liver disease. Among the 20 samples analyzed, the HCV genotype 1, subgenotype 1b, was the most frequent (60%). We report the first characterization of HCV subgenotypes 4a and 4d and the first RAS identification in patients in Colombia. Keywords: Epidemiology; Evolution; Genetic diversity; Hepatitis C virus; Infection.spa
dc.format.extent8 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherElsevierspa
dc.type.hasversioninfo:eu-repo/semantics/publishedVersionspa
dc.rightsinfo:eu-repo/semantics/openAccessspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/*
dc.titleGenetic diversity of hepatitis C virus and resistance associated substitutions to direct-acting antiviral treatment in Colombiaspa
dc.typeinfo:eu-repo/semantics/articlespa
dc.publisher.groupGrupo de Gastrohepatologíaspa
dc.identifier.doi10.1016/j.virusres.2022.198847-
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
dc.rights.accessrightshttp://purl.org/coar/access_right/c_abf2spa
dc.identifier.eissn1872-7492-
oaire.citationtitleVirus Researchspa
oaire.citationstartpage1spa
oaire.citationendpage8spa
oaire.citationvolume318spa
dc.rights.creativecommonshttps://creativecommons.org/licenses/by-nc-nd/4.0/spa
oaire.fundernameUniversidad de Antioquiaspa
oaire.fundernameColombia. Ministerio de Ciencia, Tecnología e Innovación - Minicienciasspa
dc.publisher.placeÁmsterdam, Países Bajosspa
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1spa
dc.type.redcolhttps://purl.org/redcol/resource_type/ARTspa
dc.type.localArtículo de investigaciónspa
dc.subject.decsAntivirales - Farmacología-
dc.subject.decsAntiviral Agents - Pharmacology-
dc.subject.decsColombia - Epidemiología-
dc.subject.decsColombia - Epidemiology-
dc.subject.decsFarmacorresistencia Viral-
dc.subject.decsDrug Resistance, Viral-
dc.subject.decsEnfermedad Hepática en Estado Terminal-
dc.subject.decsEnd Stage Liver Disease-
dc.subject.decsHepacivirus-
dc.subject.decsHepatitis C-
dc.subject.decsFunciones de Verosimilitud-
dc.subject.decsLikelihood Functions-
dc.subject.decsMutación Missense-
dc.subject.decsMutation, Missense-
dc.subject.decsFilogenia-
dc.subject.decsPhylogeny-
dc.subject.decsSeroepidemiologic Studies-
dc.subject.decsProteínas no Estructurales Virales-
dc.subject.decsViral Nonstructural Proteins-
dc.subject.decsEstudios Seroepidemiológicos-
dc.subject.decsHepatitis C Crónica-
dc.subject.decsHepatitis C, Chronic-
dc.description.researchgroupidCOL0024159spa
oaire.awardnumber111577757692spa
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D000998-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D003105-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D024882-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D058625-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D016174-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D006526-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D016013-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D020125-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D010802-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D016036-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D017361-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D019698-
dc.relation.ispartofjournalabbrevVirus. Res.spa
oaire.funderidentifier.rorRoR:03bp5hc83-
oaire.funderidentifier.rorRoR:03fd5ne08-
Aparece en las colecciones: Artículos de Revista en Ciencias Médicas

Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
NavasMaria_2022_GeneticDiversity_HepatitisC_resistence.pdfArtículo de investigación2.64 MBAdobe PDFVisualizar/Abrir


Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons Creative Commons